BioWorld Asia

Sep. 11, 2002

Kudos Raises £30M For Clinical Development Of Cancer Drugs

LONDON - Kudos Pharmaceuticals Ltd. raised £29.5 million (US$45.9 million) in third-round funding with plans to take its two lead cancer treatments through Phase II and push further compounds into Phase I. (Bioworld International Read More

With New Premises, Tropos Launches € 15M Funding Round

No Abstract Read More

Gene Deletion From Colorectal Tumors Might Dictate Success

Session Examines Avoiding Legal Pitfalls In Clinical Trials

Committee Provides Support For European Biotechnology

EU Legislation On GMO Exports Weak, Parliament Member Says

Medivir To Lose CEO Frick To Venture Capital Fund

MediGene Reports Positive Early Results In Liver Cancer

Avidex Third Round Raises £11.5M For T-Cell Receptors

New Controls On Genetically Modified Animals Needed In UK

ScanBalt BioRegion Looking To Create Global Biotech Region

Other News To Note

Today's news in brief

BioWorld

BioWorld briefs for July 2, 2026.

CINP 2026: Prenatal and adolescent stress shape brain vulnerability

BioWorld Science

Human biology is extraordinarily complex, and that sophistication emerges from the very beginning. During embryonic and fetal development, the organism’s...

AI-generated image for brain organoid neural research

CINP 2026: organoids reveal autism and addiction mechanisms

BioWorld Science

At the 2026 World Congress of Neuropsychopharmacology (CINP), held in Glasgow June 26-29, 2026, researchers from Japan’s National Center of Neurology and...

Ontrack Therapeutics divulges compounds for neurodegenerative diseases

BioWorld Science

Ontrack Therapeutics Ltd. has reported new heterotricyclic compounds potentially useful for the treatment of neurodegenerative diseases.

Reunion Neuroscience reports new 5-HT2A partial agonists and/or 5-HT2B antagonists

BioWorld Science

Reunion Neuroscience Inc. has identified new 5-HT2A receptor partial agonists and/or 5-HT2B receptor antagonists potentially useful for the treatment of...